MetaboGen reaches development goal – first product ready for safety study

BioGaia today announced that its´ subsidiary MetaboGen has reached an important development goal. The first version of its next generation probiotic product is now ready for a safety study.
MetaboGen focuses its research on the microbiome and on finding breakthrough opportunities that
can be developed into novel therapeutics and the next generation of probiotics. A number of
development programs are now being pursued by the company.